Last reviewed · How we verify
Melphalan, Prednisone, Lenalidomide
Melphalan is an alkylating agent that interferes with DNA replication, Prednisone is a corticosteroid that suppresses the immune system, Lenalidomide is an immunomodulatory drug that affects cell growth and survival.
Melphalan is an alkylating agent that interferes with DNA replication, Prednisone is a corticosteroid that suppresses the immune system, Lenalidomide is an immunomodulatory drug that affects cell growth and survival. Used for Multiple myeloma, Hodgkin lymphoma.
At a glance
| Generic name | Melphalan, Prednisone, Lenalidomide |
|---|---|
| Sponsor | Fondazione EMN Italy Onlus |
| Drug class | Alkylating agent, Corticosteroid, Immunomodulatory drug |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Melphalan works by attaching to DNA and interfering with its replication, leading to cell death. Prednisone suppresses the immune system by inhibiting the production of inflammatory cytokines. Lenalidomide affects cell growth and survival by modulating the activity of various signaling pathways.
Approved indications
- Multiple myeloma
- Hodgkin lymphoma
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Anemia
- Thrombocytopenia
- Neutropenia
- Infection
- Hypertension
- Hyperglycemia
Key clinical trials
- Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (PHASE4)
- A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens (PHASE2)
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma (PHASE1)
- Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients (PHASE3)
- Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients (PHASE3)
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |